Canaccord Genuity Starts Neoleukin Therapeutics (NLTX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts NLTX Hot Sheet
Price: $3.49 --0%
Rating Summary:
2 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
2 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Canaccord Genuity analyst Arlinda Lee initiates coverage on Neoleukin Therapeutics (NASDAQ: NLTX) with a Buy rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Neoleukin Therapeutics click here. For more ratings news on Neoleukin Therapeutics click here.
Shares of Neoleukin Therapeutics closed at $7.96 yesterday.
You May Also Be Interested In
- H.C. Wainwright Assumes MiNK Therapeutics (INKT) at Buy
- Berenberg Starts GomSpace Group AB (GOMX:SS) at Buy
- Bernstein SocGen Group Starts Pfizer Ltd (PFIZ:IN) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
